Suppr超能文献

ELMO3——小涎腺癌的一种负性预后标志物

ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma.

作者信息

Kotowski Ulana, Kadletz Lorenz, Schneider Sven, Oberndorfer Felicitas, Erovic Boban M, Grasl Matthaeus Ch, Lill Claudia, Heiduschka Gregor

机构信息

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

出版信息

Pathol Oncol Res. 2019 Apr;25(2):585-591. doi: 10.1007/s12253-018-0475-8. Epub 2018 Oct 29.

Abstract

Engulfment and cell motility 3 protein (ELMO3) is a protein that is involved in cell migration and promotes the remodeling of the cytoskeleton. Moreover, it is described as a prognostic marker in several cancers. The aim of this study was to evaluate ELMO3 expression in patients with minor salivary gland carcinoma. The expression of ELMO3 was examined by immunohistochemistry. The intensity of staining was evaluated and data was correlated to clinical outcome. Forty-six patients with complete clinical data were included into statistical analysis. ELMO3 expression was observed in 85% of the cases. High staining intensity of ELMO3 correlated with a significantly worse disease free survival (p = .0495) and a higher recurrence rate (p = .0071). In conclusion, it is still difficult to predict the clinical outcome of patients with minor salivary gland carcinoma. Evaluation of ELMO3 might serve as a clinical prognostic marker in future.

摘要

吞噬与细胞运动3蛋白(ELMO3)是一种参与细胞迁移并促进细胞骨架重塑的蛋白质。此外,它在几种癌症中被描述为一种预后标志物。本研究的目的是评估小涎腺癌患者中ELMO3的表达情况。通过免疫组织化学检测ELMO3的表达。评估染色强度,并将数据与临床结果相关联。46例具有完整临床数据的患者纳入统计分析。85%的病例中观察到ELMO3表达。ELMO3的高染色强度与无病生存率显著降低(p = 0.0495)和复发率较高(p = 0.0071)相关。总之,预测小涎腺癌患者的临床结果仍然困难。ELMO3评估可能在未来作为一种临床预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7870/6449284/d798648b0c5b/12253_2018_475_Fig1_HTML.jpg

相似文献

1
ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma.
Pathol Oncol Res. 2019 Apr;25(2):585-591. doi: 10.1007/s12253-018-0475-8. Epub 2018 Oct 29.
2
ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report.
Cell Oncol (Dordr). 2017 Apr;40(2):193-198. doi: 10.1007/s13402-016-0310-8. Epub 2016 Dec 30.
3
Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies.
Eur Arch Otorhinolaryngol. 2017 Jan;274(1):467-475. doi: 10.1007/s00405-016-4227-7. Epub 2016 Jul 28.
4
Minor salivary gland carcinoma: a review of 35 cases.
Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2717-26. doi: 10.1007/s00405-015-3805-4. Epub 2015 Oct 23.
5
ELMO3 predicts poor outcome in T1 laryngeal cancer.
Clin Otolaryngol. 2017 Dec;42(6):1181-1186. doi: 10.1111/coa.12845. Epub 2017 Mar 13.
6
ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Int J Clin Exp Pathol. 2015 May 1;8(5):5503-8. eCollection 2015.
7
Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer.
Biomed Res Int. 2018 Sep 24;2018:3764032. doi: 10.1155/2018/3764032. eCollection 2018.
8
The prognostic significance of β-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: β-catenin predicts overall survival.
Eur Arch Otorhinolaryngol. 2016 May;273(5):1283-92. doi: 10.1007/s00405-015-3609-6. Epub 2015 Mar 24.
10

引用本文的文献

1
Identification and analysis of key genes related to efferocytosis in colorectal cancer.
BMC Med Genomics. 2024 Aug 6;17(1):198. doi: 10.1186/s12920-024-01967-8.

本文引用的文献

1
ELMO3 predicts poor outcome in T1 laryngeal cancer.
Clin Otolaryngol. 2017 Dec;42(6):1181-1186. doi: 10.1111/coa.12845. Epub 2017 Mar 13.
2
ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report.
Cell Oncol (Dordr). 2017 Apr;40(2):193-198. doi: 10.1007/s13402-016-0310-8. Epub 2016 Dec 30.
3
Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Head Neck. 2016 Apr;38 Suppl 1:E1918-25. doi: 10.1002/hed.24349. Epub 2015 Dec 29.
4
Five- and 10-Year Cause-Specific Survival Rates in Carcinoma of the Minor Salivary Gland.
JAMA Otolaryngol Head Neck Surg. 2016 Jan;142(1):67-73. doi: 10.1001/jamaoto.2015.2805.
5
ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Int J Clin Exp Pathol. 2015 May 1;8(5):5503-8. eCollection 2015.
6
The prognostic significance of β-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: β-catenin predicts overall survival.
Eur Arch Otorhinolaryngol. 2016 May;273(5):1283-92. doi: 10.1007/s00405-015-3609-6. Epub 2015 Mar 24.
8
ELMO3: a direct driver of cancer metastasis?
Cell Cycle. 2014;13(16):2483-4. doi: 10.4161/15384101.2014.947228.
9
NSCLC metastasis: going with ELMO3.
Oncotarget. 2014 Aug 15;5(15):5850-1. doi: 10.18632/oncotarget.2341.
10
Prognostic factors in patients with minor salivary gland carcinoma of the oral cavity and oropharynx.
Head Neck. 2011 Oct;33(10):1406-12. doi: 10.1002/hed.21641. Epub 2010 Dec 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验